How bad is HAART for the HEART?

AIDS

Volumn 17, Issue 17, 2003, Pages 2529-2531

  Reiss, Peter ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antiretroviral therapy; Coronary artery disease; HIV; Non nucleoside reverse transcriptase inhibitor; Nucleoside reverse transcriptase inhibitor; Protease inhibitor

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ATHEROSCLEROSIS; BODY FAT; CARDIOTOXICITY; CORONARY ARTERY DISEASE; DRUG POTENCY; DYSLIPIDEMIA; EDITORIAL; GLUCOSE INTOLERANCE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPID STORAGE; LIPOATROPHY; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CORONARY DISEASE; HIV INFECTIONS; HIV-1; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 1642271862     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200311210-00017     Document Type: Editorial

References (13)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
2. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achar R, Leonard JM, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51-57.
3. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS 2002, 16:F1-F8.
4. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
5. van der Valk M, Gisolf EH, Reiss P, Wit FWNM, Japour A, Weverling GJ, Danner SA on behalf of the Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001, 15:847-855.
6. Bastard J-P, Caron M, Vidai H, Jan V, Auclair M, Vigouroux C, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002, 359:1026-1031.
7. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999, 354:1112-1115.
8. Seminari E, Pan A, Voltini G, Carnevale C, Maserati R, Minoli L, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002, 162:433-438.
9. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710.
10. Friis-Møller N, Weber R, d'Arminio Monforte A, El-Sadr W, Reiss P, Dabis F, et al. Exposure to HAART is associated with an increased risk of myocardial infarction: The D:A:D study. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 130].
11. Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, Guerin T, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003, 111:389-397.
12. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M for the Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002, 185: 456-462.
13. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001, 15:2407-2414.